Table 1.
Patient characteristics.
| N (%) or Mean [SD] | |
|---|---|
| Number of patients | 101 |
| Age (years) | 78.6 [12.1] |
| Male gender | 61 (67.4%) |
| With active cancer | 30 (29.7%) |
| Number of comorbid conditions | |
| 0 | 3 (3.0%) |
| 1 | 25 (24.8%) |
| 2 | 37 (36.6%) |
| ≥3 | 36 (35.6%) |
| Healthcare-associated infection | 17 (17.0%) |
| Septic shock associated with BSI | 13 (12.9%) |
| Department at the time of BSI diagnosis | |
| Medical Department | 95 (94.1%) |
| Intensive Care Unit | 6 (5.9%) |
| Site of infection | |
| Urinary tract | 59 (58.4%) |
| Gastrointestinal | 22 (21.8%) |
| Pulmonary | 6 (5.9%) |
| Vascular catheter | 5 (5.0%) |
| Other | 9 (8.9%) |
| Type of Enterobacterales | |
| ESCPM group | 18 (17.8%) |
| Other Enterobacterales | 83 (82.2%) |
| qPitt score for BSI severity | |
| <2 | 83 (82.2%) |
| ≥2 | 18 (17.8%) |
| ESBL | 8 (8.2%) |
| Effective empirical treatment | |
| No | 21 (21.0%) |
| Yes | 79 (79.0%) |
| Type of empirical antimicrobial therapy | |
| Single therapy | 60 (62.5%) |
| Combination therapy | 36 (37.5%) |
| Clinical stability at 48 h | |
| No | 32 (31.7%) |
| Yes | 69 (68.3%) |
| In-hospital death | 24 (23.8%) |
| Death probably related to BSI | |
| No | 4 (16.7%) |
| Yes | 20 (83.3%) |
| Clinical instability at 48 h or death | 36 (35.6%) |
| Recurrent BSI within 14 days | 3 (3.0%) |
BSI: bloodstream infection; ESCPM group: Enterobacter spp., Serratia marcescens, Citrobacter freundii, Providencia spp., and Morganella morganii.